Phase Ii Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with Cd30 Expression

Background: Brentuximab vedotin (BV) is an anti-CD30 chimeric antibody conjugated by a protease-cleavable linker to the microtubule-disrupting agent, MMAE. While CD30 expression of malignant cells in HL and ALCL is uniform, in mycosis fungoides/Sezary syndrome (MF/SS), the CD30 expression is more variable. We reported previously (ASH 2012) that BV has clinical activity in MF/SS across all CD30 expression levels. In this final report, we update the clinical data and present new biomarker and correlative tissue analyses.